3585-48-6

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, α-methyl-4-(1-methylethyl)-, is used as an impurity in the manufacturing process of Ibuprofen for its role in the development of nonsteroidal anti-inflammatory drugs (NSAIDs). The presence of Benzeneacetic acid, a-methyl-4-(1-methylethyl)- in Ibuprofen production is significant due to its contribution to the overall efficacy of the drug, particularly in its (S)-isomer form, which is responsible for the primary pharmacological activity.
Additionally, given its structural similarity to Ibuprofen, further research into Benzeneacetic acid, α-methyl-4-(1-methylethyl)-, may reveal potential applications in the development of new pharmaceuticals with similar or improved anti-inflammatory properties. This could lead to the creation of novel therapeutic agents for the treatment of various inflammatory conditions and pain management.

Upstream product

• 124-38-9 carbon dioxide 
• 59770-99-9 (+/-)-1-bromo-1-(4-isopropylphenyl)ethane 
• 645-13-6 4-isopropylacetophenone 

Relevant academic research and scientific papers

A Core–Shell-Structured Silver Nanowire/Nitrogen-Doped Carbon Catalyst for Enhanced and Multifunctional Electrofixation of CO2

Numerous catalysts have been successfully introduced for CO2 fixation in aqueous or organic systems. However, a single catalyst showing activity in both solvent types is still rare, to the best of our knowledge. We developed a core–shell-structured AgNW/NC700 composite using a Ag nanowire (NW) core encapsulated by a N-doped carbon (NC) shell at 700 °C. Through control experiments and density functional theory calculations, it was confirmed that Ag nanowires acted as the active sites for CO2 fixation and the uniformly coating of N-doped carbon created a CO2-rich environment around the Ag nanowires, which could significantly improve the catalytic activity of Ag nanowires for electrochemical CO2 fixation. Under mild conditions, up to 96 % faradaic efficiency of CO, 95 % yield of Ibuprofen and 92 % yield of propylene carbonate could be obtained in the electrochemical CO2 direct reduction, carboxylation and cycloaddition, respectively, using the same AgNWs/NC700 catalyst. These results might provide an alternative strategy for efficient electrochemical fixation of CO2.

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors

The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.

Chemoenzymatic synthesis of pure enantiomeric 2-aryl propionic acids

A new chemoenzymatic procedure to obtain pure enantiomeric 2-arylpropionic acids is described. The one pot synthesis of (±)-2-arylpropionic acids is carried out by addition of dichlorocarbene to the C=O bond of arylmethylketones and hydrogenolysis of the additon product. The racemic mixture is resolved by enantiospecific hydrolysis of the racemic ethyl esters using native lipase from Candida rugosa. The good yields, the accessibility of the starting arylmethylketones and the stereospecificity of the enzymatic hydrolysis make the process interesting in order to obtain the same non steroidal antiinflammatory drugs such as Ibuprofen or Naproxen.